Equillium (NASDAQ:EQ) COO Sells $300,780.00 in Stock

Equillium, Inc. (NASDAQ:EQ) COO Christine Zedelmayer sold 120,312 shares of the business’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $2.50, for a total value of $300,780.00. Following the transaction, the chief operating officer directly owned 62,586 shares of the company’s stock, valued at approximately $156,465. This represents a 65.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Christine Zedelmayer also recently made the following trade(s):

• On Monday, March 9th, Christine Zedelmayer sold 181,219 shares of Equillium stock. The shares were sold at an average price of $2.00, for a total transaction of $362,438.00.
• On Thursday, February 19th, Christine Zedelmayer sold 185,937 shares of Equillium stock. The stock was sold at an average price of $1.76, for a total transaction of $327,249.12.
• On Tuesday, December 23rd, Christine Zedelmayer sold 100,000 shares of Equillium stock. The stock was sold at an average price of $1.50, for a total transaction of $150,000.00.

Equillium Trading Down 6.1%

Shares of NASDAQ:EQ traded down $0.15 during trading hours on Monday, reaching $2.32. The stock had a trading volume of 990,114 shares, compared to its average volume of 545,806. Equillium, Inc. has a 1 year low of $0.27 and a 1 year high of $2.70. The firm’s 50 day moving average is $1.54 and its 200-day moving average is $1.41.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on EQ. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Equillium in a research report on Monday, December 29th. Zacks Research upgraded shares of Equillium to a “hold” rating in a research note on Thursday, February 26th. Wall Street Zen upgraded shares of Equillium from a “sell” rating to a “hold” rating in a research note on Saturday. Roth Mkm began coverage on shares of Equillium in a research report on Friday. They set a “buy” rating and a $12.00 price objective for the company. Finally, Stifel Nicolaus assumed coverage on shares of Equillium in a report on Wednesday, February 25th. They issued a “buy” rating and a $5.00 target price for the company. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $6.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. ADAR1 Capital Management LLC boosted its stake in shares of Equillium by 0.9% during the fourth quarter. ADAR1 Capital Management LLC now owns 5,608,078 shares of the company’s stock worth $8,693,000 after buying an additional 48,090 shares during the period. Janus Henderson Group PLC purchased a new position in Equillium in the 4th quarter valued at $9,057,000. Balyasny Asset Management L.P. raised its position in Equillium by 3.6% during the 4th quarter. Balyasny Asset Management L.P. now owns 2,076,250 shares of the company’s stock worth $3,218,000 after buying an additional 72,602 shares during the last quarter. Cantor Fitzgerald L. P. boosted its holdings in shares of Equillium by 32.4% in the fourth quarter. Cantor Fitzgerald L. P. now owns 562,643 shares of the company’s stock valued at $872,000 after acquiring an additional 137,643 shares in the last quarter. Finally, Diadema Partners LP lifted its position in Equillium by 15.8% in the fourth quarter. Diadema Partners LP now owns 347,393 shares of the company’s stock valued at $538,000 after purchasing an additional 47,393 shares during the period. 27.05% of the stock is owned by hedge funds and other institutional investors.

About Equillium

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.